Northern Trust
ALLO icon

Northern Trust’s Allogene Therapeutics ALLO Stock Holding History

Northern Trust’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.14M Buy
1,285,702
+87,235
+7% +$175K ﹤0.01% 2717
2025
Q4 		$1.64M Sell
1,198,467
-81,161
-6% -$107K ﹤0.01% 3110
2025
Q3 		$1.59M Buy
1,279,628
+5,336
+0.4% +$6.36K ﹤0.01% 3159
2025
Q2 		$1.44M Buy
1,274,292
+79,882
+7% +$106K ﹤0.01% 3187
2025
Q1 		$1.74M Sell
1,194,410
-110,822
-8% -$209K ﹤0.01% 2991
2024
Q4 		$2.78M Buy
1,305,232
+56,693
+5% +$140K ﹤0.01% 2834
2024
Q3 		$3.5M Buy
1,248,539
+210,434
+20% +$561K ﹤0.01% 2686
2024
Q2 		$2.42M Buy
1,038,105
+67,038
+7% +$198K ﹤0.01% 2794
2024
Q1 		$4.34M Sell
971,067
-43,278
-4% -$181K ﹤0.01% 2563
2023
Q4 		$3.26M Buy
1,014,345
+153,818
+18% +$436K ﹤0.01% 2720
2023
Q3 		$2.73M Sell
860,527
-1,979
-0.2% -$8.67K ﹤0.01% 2768
2023
Q2 		$4.29M Buy
862,506
+63,333
+8% +$343K ﹤0.01% 2584
2023
Q1 		$3.95M Sell
799,173
-31,231
-4% -$200K ﹤0.01% 2599
2022
Q4 		$5.22M Sell
830,404
-335,206
-29% -$3.1M ﹤0.01% 2458
2022
Q3 		$12.6M Buy
1,165,610
+413,301
+55% +$5.62M ﹤0.01% 1823
2022
Q2 		$8.58M Buy
752,309
+53,229
+8% +$473K ﹤0.01% 2141
2022
Q1 		$6.37M Sell
699,080
-25,637
-4% -$267K ﹤0.01% 2437
2021
Q4 		$10.8M Buy
724,717
+11,215
+2% +$198K ﹤0.01% 2179
2021
Q3 		$18.3M Sell
713,502
-21,592
-3% -$513K ﹤0.01% 1862
2021
Q2 		$19.2M Buy
735,094
+86,630
+13% +$2.47M ﹤0.01% 1916
2021
Q1 		$22.9M Sell
648,464
-20,143
-3% -$679K ﹤0.01% 1717
2020
Q4 		$16.9M Sell
668,607
-12,980
-2% -$423K ﹤0.01% 1915
2020
Q3 		$25.7M Buy
681,587
+8,969
+1% +$338K 0.01% 1433
2020
Q2 		$28.8M Buy
672,618
+154,124
+30% +$5.57M 0.01% 1320
2020
Q1 		$10.1M Buy
518,494
+6,479
+1% +$154K ﹤0.01% 1864
2019
Q4 		$13.3M Sell
512,015
-15,965
-3% -$440K ﹤0.01% 1993
2019
Q3 		$14.4M Buy
527,980
+216,959
+70% +$6.18M ﹤0.01% 1913
2019
Q2 		$8.35M Buy
311,021
+20,971
+7% +$584K ﹤0.01% 2262
2019
Q1 		$8.38M Buy
290,050
+3,810
+1% +$111K ﹤0.01% 2260
2018
Q4 		$7.71M Buy
+286,240
New +$7.6M ﹤0.01% 2234

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust's ALLO Position: Q1 2026 in Review

Northern Trust increased its Allogene Therapeutics (ALLO) stake by 7.3% in Q1 2026, buying an estimated $175K and bringing the position to 1,285,702 shares worth $3.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2717.

Northern Trust first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $28.8M in Q2 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Northern Trust held 1,285,702 shares of Allogene Therapeutics worth $3.14M as of Q1 2026.
  • Northern Trust bought 87,235 Allogene Therapeutics shares in Q1 2026, an estimated $175K.
  • Allogene Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2717 holding.
  • Northern Trust first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Northern Trust's Allogene Therapeutics position peaked at $28.8M in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.